• 제목/요약/키워드: Omeprazole

검색결과 124건 처리시간 0.032초

Omeprazole-cholestyramine resin 제제의 위산분비에 대한 억제효과 (The Inhibitory effect of omeprazole-cholestyramine resin in gastric secretion of rat)

  • 이영욱;김일웅;정지훈;라현오;최경범;이남인;손의동;허인회
    • Biomolecules & Therapeutics
    • /
    • 제8권4호
    • /
    • pp.318-324
    • /
    • 2000
  • We have examined inhibitory erects on gasritis using omeprazole-cholestyramine resinate, which has been developed to increase the stability of omeprazole, the well-known proton pump inhibitor, in an acidic condition. To test the pharmacological action of this, we investigated the effect of omeprazole-cholestyramine resinate on indomethacin-induced gastritis in rats. Omeprazole was used as a reference drug. Orally administered omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate on the gastritis was similar to that of reference drug. In addition, rectal adminstration of the omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate was equipotent to reference drug. The basal gastric acid secretion was decreased when it was administered either orally or rectally. This inhibition of omfprazole-cholestyramine resinate was similar to that of omeprazole. These data suggest that omeprazole-cholestyramine resinate inhibit the gastritis in rats, and are comparable to omeprazole available in market.

  • PDF

L-아르기닌이 오메프라졸의 안정성에 미치는 효과 (Effect of L-arginine on the Stability of Omeprazole)

  • 이은진;한경두;신희종;김정우;김종국
    • Journal of Pharmaceutical Investigation
    • /
    • 제27권1호
    • /
    • pp.23-27
    • /
    • 1997
  • To investigate the effect of L-arginine as stabilizing agent for omeprazole, the degradation rate constant of omeprazole in aqueous solution was determined at 30, 40 and $50^{\circ}C$ with various ratios of L-arginine to omeprazole. The pH of omeprazole solutions was also determined. As the amount of L-arginine increased, the pH of omeprazole solution also increased, and the solution appeared to be more stable. The omeprazole in aqueous solution could be stabilized by more than 15:1 molar ratio of L-arginine to omeprazole. The stability of omeprazole in commercial products using L-arginine or sodium phosphate dibasic as stabilizing agent was investigated. Among the commercial products, the omeprazole product prepared with L-arginine (molar ratio of L-arginine to omeprazole, 20:1) was most stable.

  • PDF

Omeprazole 체내 동태의 약물유전학적 특성에 관한 연구

  • 신상구;장인진;신재국;손동렬
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
    • /
    • pp.334-334
    • /
    • 1994
  • Omeprazole의 약동학적 Parameter는 tmax를 제외하고 두 군간에 유의한 (p<0.001) 차이론 보였다 : AUC의 평균치는 5-mephenytoin hydroxylation poor metabol izer에서 extensive metabol izer에 비해 약 6-7배 컸다. Omeprazole sulfone의 parameter는 omeprazole에서 관찰된 두 군간의 차이와 유사하였다. 그러나 5-hydroxyomeprazole의 경우에는 Cmax, AUC 등이 extensive metabolizer에서 더컸다. Omeprazole의 청소율은 S-mephenytoin hydroxylation 대사능(MR)과 유의한 상잔관계(rs=0.79, p<0.01)를 보였으며, omeprazole과 그 대사물(5-hydroxyomeprazole 및 omeprazole sulfone)의 반감기 또한 S-mephenytoin hydroxylation 대사능과 유의한 상관성을 보였다.

  • PDF

오메프라졸 구강점막 부착정제에 관한 연구 (Oral Mucosal Adhesive Tablets of Omeprazole)

  • 정재희;최한곤;박선주;유제만;윤성준
    • Journal of Pharmaceutical Investigation
    • /
    • 제27권2호
    • /
    • pp.133-137
    • /
    • 1997
  • Buccal absorption test of omeprazole in human was performed to determine the permeability of the drug molecule through oral mucous membrane. Oral mucosal adhesive tablets of omeprazole were prepared by compressing the omeprazole with a mixture of sodium alginate and hydroxypropylmethyl cellulose (HPMC) as bioadhesive polymers, magnesium oxide (MgO) as a stabilizer and sodium carboxymethyl cellulose (Na CMC) or cros-carmellose sodium (Ac-Di-Sol) as disintegrants. The bioadhesive force, stability in saliva and release characteristics of the tablets were evaluated. Omeprazole was absorbed about 23% in 15 min through human buccal mucous membrane. Furthermore, omeprazole was stable in saliva for more than 8 hrs when MgO was added to the tablet as the amount of 2.5 fold of omeprazole. The release rate of omeprazole was increased with increasing the amount of sodium alginate in the tablet. From these results, it is suggested that tablets composed of [omeprazole/HPMC/sodium alginate/MgO/Ac-Di-Sol and/or Na CMC (20/6/24/50/10) (mg/tablet)] are potential candidate for buccal drug delivery system.

  • PDF

Omeprazole 수지염의 흰쥐와 토끼에서의 위장관내 산도변화에 따른 흡수변화 및 교차시험법에 의한 약물동태연구 (Pharmacokinetics of Omeprazole-Resin by Crossover Design and the Variation of Absorption upon pH Change in the Guts of the Rat and the Rabbit)

  • 권광일;심상호
    • 약학회지
    • /
    • 제39권4호
    • /
    • pp.401-410
    • /
    • 1995
  • Pharmacolinetic profiles of omeprazole enteric coated granules including Ramezole$^\circledR$, Losec$^\circledR$, omeprazole-Na and omeprazole-resin salt were studied using the crossover design in rats and rabbits. The absorption variance of the preparations at the altered pH condition of the gastrointestinal tract was also studied. After oral administration of four omeprazole enteric coated pellets (10mg/kg) with and without concomitant administration NaHCO$_{3}$ (5 mg/ml, 60 mM) in the rats, the differences of absorplion rate and extent were evaluated. In the NaHCO$_{3}$, administration group, the T$_{max}$ appeared to be 2~10 times shorter than water administration group, and the $C_{max}$ also increased to about 4 times, and the AUC increased to about 2.5 times. Pharmacokinetic parameters of four omeprazole enteric coated pellets in rats showed no statistical significance (ANOVA, P>0.05) in both groups. In the crossover study, the second dosed drug showed 4~5 times increased bioavailability than first dosed drug, which shows the strong carry-over effect of acid secretion of the first dosed drug. The differences of the pharmacokinetic parameters of the two test formulations (Losec$^\circledR$ and omeprazole-resin) showed no statistical significance.

  • PDF

아르기닌 또는 인산일수소나트륨이 수용액중에서 오메프라졸의 안정성에 미치는 영향 비교 (Effect of Arginine or Sodium Phosphate Dibasic on the Stability of Omeprazole in Aqueous Solution)

  • 심창구;한용해;우종수;이창현
    • Journal of Pharmaceutical Investigation
    • /
    • 제23권4호
    • /
    • pp.225-229
    • /
    • 1993
  • The stability of omeprazole in the aqueous solutions containing arginine or sodium phosphate dibasic(SPD) was examined at 30, 40 and $50^{\circ}C$. Arginine or anhydrous SPD was added to omeprazoie solution ($200{\mu}g/\;ml$ in distilled water) to yield $100{\mu}g/\;ml$ concentration of each. Then, the solution was kept at 30, 40 or $50^{\circ}C$ for 90 hrs. Aliquots of the solution were withdrawn at specified time intervals and assayed by HPLC for intact omeprazole. The remaining percentage-time curves revealed that omeprazole was degraded rapidly as funtions of time and temperature following pseudo first-order kinetics. The rate constant in the SPD solution was much higher than in the arginine solution. In other words. the degradation half-lives of omeprazole at $30^{\circ}C$, for example, was 148 and 76 hr in arginine and SPD solutions respectively. The initial pH of the solution containing $100{\mu}g/\;ml$ of arginine or SPD was 9.7 or 8.7, respectively. Since omeprazole is more stable as the pH of its solution becomes more alkaline, the longer half-life of omeprazole in arginine solution could be explained by the more alkaline characteristics of arginine than SPD in the solution. The activation energy necessary for the degradation reaction was almost identical in both solutions, indicating similar degradation mechanisms of omeprazole in the solutions. In conclusion, omprazole was more stable in the presence of arginine than of SPD.

  • PDF

장용정 Omeprazole정제와 캅셀제의 액제화 투여 방법의 용출시험 (Dissolution Test to Optimize Liquid Formulations for Enteric Coated Tablets and Capsules Containing Enteric Coated Granules of Omeprazole)

  • 장혜정;이숙향
    • 한국임상약학회지
    • /
    • 제11권1호
    • /
    • pp.13-18
    • /
    • 2001
  • Omeprazole is usually administered as encapsulated enteric-coated granules and enteric-coated tablets because of its acid-labile nature. For children and patients who can not swallow, it can be mixed with water or other liquid after a capsule is opened or a tablet is crushed. This study was performed to compare omeprazole liquid formulations of tablet and capsule Omeprazole 20 mg capsule containing enteric coated granules was opened and 20 mg entric-coated tablet was ground to be mixed with sodium bicarbonate solution, orange juice or water. Each liquid formulation was poured into dissolution tester, mixed with first solution (artificial gastric juice; pH 1.2) for two hours, then with second solution (artifical enteric juice; pH 6.8) for thirty minutes. pH was measured periodically for two and half hours. Samples were drawn periodically, mixed with lansoprazole as an internal standard, and injected to HPLC. As results, pH of sodium bicarbonate solution of omeprazole was significantly higher than that of orange juice or water in first solution (6.2-7.4 vs. 1.2, p<0.005). At 150 min, concentrations of omeprazole in three diluents with granules and in sodium bicarbonate solution of tablet powder sustained significantly higher than in other solution of tablet powder (p<0.001). In conclusion, enteric-coated granules from capsule with three diluents and powder from tablet in sodium bicarbonate solution was stable during dissolution test, which would be appropriate and recommended for patient who can not swallow solid preparations.

  • PDF

소화성궤양시 병용약물이 수용액 중의 오메프라졸 안정성에 미치는 영향 (Effect of Other Medications on the Stability of Omeprazole in Aqueous Solution for the Peptic Ulcer Disease)

  • 이영재;황완균;조성완
    • 한국산학기술학회논문지
    • /
    • 제10권11호
    • /
    • pp.3494-3499
    • /
    • 2009
  • 소화성 궤양의 치료에 일반적으로 병용되어 사용되는 소염진통제인 록소프로펜 또는 알칼리화제인 탄산수소나트륨을 함유한 수용액 중에서 소화성 궤양의 치료에 사용되는 오메프라졸의 안정성에 대한 영향이 실온상태에서 실험하였다. 록소프로펜과 탄산수소나트륨 각각 60 mg을 오메프라졸(600 ${\mu}g$/ml) 용액에 혼합한 후 그 용액을 실온 상태로 80시간 보존하면서 그 분해정도를 원래의 오메프라졸의 농도와 비교하여 각각의 소실 농도를 산출하였다. 오메프라졸의 농도와 크로마토그램의 면적비는 5 - 160 ${\mu}g$/ml 농도에서 상호 직선성을 나타내었고 상대 표준 편차는 3.05 %이하로서 분석이 제대로 이루어졌음을 확인할 수 있었으며 함유 약물과 시간에 따른 오메프라졸의 분해 양상은 가상의 일차 직선 속도식을 나타내는 것을 알 수 있었다. 결론적으로 오메프라졸은 탄산수소나트륨 또는 록소프로 펜과의 병용 투여에 의해 그 안정성이 영향을 받을 수 있다는 것을 확인할 수 있었다.

위-식도 역류질환의 수술적 치료 (Surgical Treatment of Gastroesophageal Reflux Disease)

  • 송교영
    • 대한기관식도과학회지
    • /
    • 제19권1호
    • /
    • pp.11-14
    • /
    • 2013
  • Gastro-esophageal reflux disease (GERD) is a recurrent, long-term gastrointestinal condition characterised by the abnormal reflux of stomach contents into the esophagus. Heartburn is the most dominant symptom, which can be life long and can considerably reduce quality of life. The main goals of treatment are to alleviate symptoms and prevent relapses, esophageal stricture and adenocarcinoma. This paper presents a review comparing the effectiveness of omeprazole with Nissen fundoplication surgery for the treatment of GERD. Nissen fundoplication is more effective in controlling heartburn symptoms, healing esophagitis and preventing relapses than omeprazole. Quality of life, in terms of productivity and ability to work, is difficult to assess in the omeprazole group and, as a result, a comparison of this aspect is limited. Although fundoplication is expensive in the short term, it is more cost-effective than omeprazole. Nurses need to be aware of the effectiveness of omeprazole and fundoplication to provide patients with accurate information, which assists patients in decision making regarding treatment options.

  • PDF

Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants

  • Azizollahi, Hamid Reza;Rafeey, Mandana
    • Clinical and Experimental Pediatrics
    • /
    • 제59권5호
    • /
    • pp.226-230
    • /
    • 2016
  • Purpose: Gastroesophageal reflux disease (GERD) occurs in pediatric patients when reflux of gastric contents presents with troublesome symptoms. The present study compared the effects of omeprazole and ranitidine for the treatment of symptomatic GERD in infants of 2-12 months. Methods: This study was a clinical randomized double-blind trial and parallel-group comparison of omeprazole and ranitidine performed at Children Training Hospital in Tabriz, Iran. Patients received a standard treatment for 2 weeks. After 2 weeks, the patients with persistent symptoms were enrolled in this randomized study. Results: We enrolled 76 patients in the present study and excluded 16 patients. Thirty patients each were included in group A (ranitidine) and in group B (omeprazole). GERD symptom score for groups A and B was $47.17{\pm}5.62$ and $51.93{\pm}5.42$, respectively, with a P value of 0.54, before the treatment and $2.47{\pm}0.58$ and $2.43{\pm}1.15$, respectively, after the treatment (P=0.98). No statistically significant differences were found between ranitidine and omeprazole in their efficacy for the treatment of GERD. Conclusion: The safety and efficacy of ranitidine and omeprazole have been demonstrated in infants. Both groups of infants showed a statistically significant decrease in the score of clinical variables after the treatment.